Eberhard F. Mammen (1930–2008).
Welcome to the latest of our Eberhard F. Mammen award announcements. As noted previously,[1]
[2]
[3] Thieme, the publisher of Seminars in Thrombosis & Hemostasis, has created the “Eberhard F. Mammen Excellence in Thrombosis and Hemostasis Awards” in honor of Eberhard F. Mammen and in recognition of his contribution to this field
and to the journal that he both founded and steered for more than three decades. These
awards began in 2009, under two categories: “Most Popular Article Awards” and “Young
Investigator Awards.” Current details and conditions of the award can be summarized
as:
-
Most Popular article awards: Awarded to the authors of the most popular articles published in Seminars in Thrombosis & Hemostasis. The awards are determined by the Editor in Chief on the basis of user statistics
from Thieme e-Journals from the preceding 2 years. Prefaces, Errata, Letters to the
Editor, Editorials, and previous award winners are excluded from further consideration
of these awards, which currently comprise two categories: one for “open access” articles
and another for a “general category.” There are two major cash prizes of US$1,000
for each category. In addition, winners of the “general category” awards are granted
“open access” status for these articles thereafter.
-
Young Investigator awards: Best presentation or meeting abstract by a young investigator—as presented or delivered
to an international or large regional meeting on a topic related to the fields of
thrombosis and hemostasis, and whose subject matter is determined to be in the spirit
of Dr. Mammen. Up to six cash prizes of US$1,000 in any year. There are some additional
considerations and conditions for the award, and awardees are expected to prepare
a review or other article related to the topic of their presentation for publication
in Seminars in Thrombosis & Hemostasis.
Further details of the awards and the award winners are posted online (http://www.thieme.com/sth), and previous award winner announcements are also available in print.[4]
[5]
[6]
[7]
[8]
[9]
[10]
[11]
It is, therefore, with great pleasure that we would like to announce the latest winners
of the 2015 Eberhard F. Mammen awards for the most popular articles from Seminars in Thrombosis & Hemostasis for the period of 2013 to 2014 inclusive. We will be announcing the young investigator
awards related to meetings held in the recent past at a forthcoming opportunity.
2015 “Most Popular” Article Awards
As mentioned, the Most Popular article awards are given to the authors of the most
popular articles published in Seminars in Thrombosis & Hemostasis as determined on the basis of user statistics from the publisher of this journal
and covering the preceding 2-year period. Thus, the 2015 “Most Popular” awards are
granted to the most popular articles from 2013 to 2014 inclusive. Because of an increasing
trend to publish in an open access mode, and due to ongoing presence of many of the
previous “Most Popular” awardees (now also open access) on the top 100 listing of
most popular, this may generate an inequitable advantage for these in terms of download
statistics. Accordingly, the publisher of Seminars in Thrombosis & Hemostasis has established a separate category of the award for “open access” articles, and
the most popular articles are now listed in two separate tables. [Table 1] lists the top 25 downloaded nonopen access articles from Seminars in Thrombosis & Hemostasis (2013 and 2014 inclusive), and thus eligible for the “general category” award.[12]
[13]
[14]
[15]
[16]
[17]
[18]
[19]
[20]
[21]
[22]
[23]
[24]
[25]
[26]
[27]
[28]
[29]
[30]
[31]
[32]
[33]
[34]
[35]
[36] [Table 2] lists the top 25 downloaded open access articles from Seminars in Thrombosis & Hemostasis (2013 and 2014 inclusive), including previous winners of this award.[37]
[38]
[39]
[40]
[41]
[42]
[43]
[44]
[45]
[46]
[47]
[48]
[49]
[50]
[51]
[52]
[53]
[54]
[55]
[56]
[57]
[58]
[59]
[60]
[61] As previously highlighted in these editorials,[9]
[10] previous winners of the award are not eligible for another award for the same article;
hence, many of the articles listed in [Table 2] do not qualify for an award in 2015. The notable exceptions are the other top-listed
articles, the first two of which have, therefore, been granted the award,[41]
[43] with both being published in 2013. The two top-listed articles[12]
[13] in [Table 1] are winners of the 2015 Eberhard F. Mammen award for most popular article within
the “general category”), both also being published in 2013. Accordingly, the 2015
Eberhard F. Mammen award winners for most popular article (2014/2014 inclusive) are
as follows:
Table 1
Most popular papers from Seminars in Thrombosis & Hemostasis in 2013/2014 “general category”
|
Rank, citation
|
|
1. Tapson VF. Thrombolytic therapy for acute pulmonary embolism. Semin Thromb Hemost
2013;39(4):452–458
|
|
2. George JN, Charania RS. Evaluation of patients with microangiopathic hemolytic
anemia and thrombocytopenia. Semin Thromb Hemost 2013;39(2):153–160
|
|
3. Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost 2013;39(5):559–566
|
|
4. de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an
update. Semin Thromb Hemost 2013;39(6):585–595
|
|
5. Scharf RE. Drugs that affect platelet function. Semin Thromb Hemost 2012;38(8):865–883
|
|
6. Federici AB, Budde U, Castaman G, Rand JH, Tiede A. Current diagnostic and therapeutic
approaches to patients with acquired von Willebrand syndrome: a 2013 update. Semin
Thromb Hemost 2013;39(2):191–201
|
|
7. Franchini M, Coppola A, Tagliaferri A, Lippi G. FEIBA versus NovoSeven in hemophilia
patients with inhibitors. Semin Thromb Hemost 2013;39(7):772–778
|
|
8. Barbano B, Gigante A, Amoroso A, Cianci R. Thrombosis in nephrotic syndrome. Semin
Thromb Hemost 2013;39(5):469–476
|
|
9. Lacroix R, Robert S, Poncelet P, Dignat-George F. Overcoming limitations of microparticle
measurement by flow cytometry. Semin Thromb Hemost 2010;36(8):807–818
|
|
10. McMahon B, Stein BL. Thrombotic and bleeding complications in classical myeloproliferative
neoplasms. Semin Thromb Hemost 2013;39(1):101–111
|
|
11. Barco S, Nijkeuter M, Middeldorp S. Pregnancy and venous thromboembolism. Semin
Thromb Hemost 2013;39(5):549–558
|
|
12. Franchini M, Coppola A, Rocino A, et al; Italian Association of Hemophilia Centers
(AICE) Working Group. Systematic review of the role of FVIII concentrates in inhibitor
development in previously untreated patients with severe hemophilia a: a 2013 update.
Semin Thromb Hemost 2013;39(7):752–766
|
|
13. Tagalakis V, Wharin C, Kahn SR. Comprehensive update on the prevention and treatment
of venous thromboembolism in cancer patients. Semin Thromb Hemost 2013;39(2):127–140
|
|
14. Monagle P. Diagnosis and management of deep venous thrombosis and pulmonary embolism
in neonates and children. Semin Thromb Hemost 2012;38(7):683–690
|
|
15. Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics. Semin Thromb Hemost
2003;29(5):435–450
|
|
16. Schroeder V, Kohler HP. Factor XIII deficiency: an update. Semin Thromb Hemost
2013;39(6):632–641
|
|
17. Lippi G, Mattiuzzi C, Favaloro EJ. Novel and emerging therapies: thrombus-targeted
fibrinolysis. Semin Thromb Hemost 2013;39(1):48–58
|
|
18. Declerck PJ, Gils A. Three decades of research on plasminogen activator inhibitor-1:
a multifaceted serpin. Semin Thromb Hemost 2013;39(4):356–364
|
|
19. Stasi R. Immune thrombocytopenia: pathophysiologic and clinical update. Semin
Thromb Hemost 2012;38(5):454–462
|
|
20. Duga S, Salomon O. Congenital factor XI deficiency: an update. Semin Thromb Hemost
2013;39(6):621–631
|
|
21. Barrowcliffe TW, Raut S, Sands D, Hubbard AR. Coagulation and chromogenic assays
of factor VIII activity: general aspects, standardization, and recommendations. Semin
Thromb Hemost 2002;28(3):247–256
|
|
22. Di Minno A, Spadarella G, Prisco D, Franchini M, Lupoli R, Di Minno MN. Clinical
judgment when using coagulation tests during direct oral anticoagulant treatment:
a concise review. Semin Thromb Hemost 2013;39(7):840–846
|
|
23. Lippi G, Favaloro EJ, Cervellin G. Prevention of venous thromboembolism: focus
on mechanical prophylaxis. Semin Thromb Hemost 2011;37(3):237–251
|
|
24. Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin
Thromb Hemost 2004;30(5):579–589
|
|
25. Prechel M, Walenga JM. Heparin-induced thrombocytopenia: an update. Semin Thromb
Hemost 2012;38(5):483–496
|
Table 2
Most popular papers from Seminars in Thrombosis & Hemostasis in 2013/2014 “open access” category
|
Rank, citation
|
Award won in previous years?
|
|
1. Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and
cardiovascular disease risk: beyond the “French paradox”. Semin Thromb Hemost 2010;36(1):59–70
|
2012
|
|
2. Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost
2005;31(4):381–392
|
2009
|
|
3. Rak J. Microparticles in cancer. Semin Thromb Hemost 2010;36(8):888–906
|
2012
|
|
4. Mariani G, Bernardi F. Factor VII Deficiency. Semin Thromb Hemost 2009;35(4):400–406
|
2011
|
|
5. Hylek EM. Anticoagulation therapy for atrial fibrillation. Semin Thromb Hemost
2013;39(2):147–152
|
–
|
|
6. Tufano A, Guida A, Di Minno MN, Prisco D, Cerbone AM, Di Minno G. Prevention of
venous thromboembolism in medical patients with thrombocytopenia or with platelet
dysfunction: a review of the literature. Semin Thromb Hemost 2011;37(3):267–274
|
2013
|
|
7. Rojas-Hernandez CM, Garcia DA. The novel oral anticoagulants. Semin Thromb Hemost
2013;39(2):117–126
|
–
|
|
8. Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding
disorders. Semin Thromb Hemost 2012;38(7):673–682
|
–
|
|
9. Fava C, Montagnana M, Favaloro EJ, Guidi GC, Lippi G. Obstructive sleep apnea syndrome
and cardiovascular diseases. Semin Thromb Hemost 2011;37(3):280–297
|
2013
|
|
10. Lippi G, Favaloro EJ, Meschi T, Mattiuzzi C, Borghi L, Cervellin G. E-cigarettes
and cardiovascular risk: beyond science and mysticism. Semin Thromb Hemost 2014;40(1):60–65
|
–
|
|
11. Italiano JE Jr. Unraveling mechanisms that control platelet production. Semin
Thromb Hemost 2013;39(1):15–24
|
–
|
|
12. Salmela B, Joutsi-Korhonen L, Armstrong E, Lassila R. Active online assessment
of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation
analysis. Semin Thromb Hemost 2012;38(1):23–30
|
2014
|
|
13. Cuker A. Clinical and laboratory diagnosis of heparin-induced thrombocytopenia:
an integrated approach. Semin Thromb Hemost 2014;40(1):106–114
|
–
|
|
14. Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008;34(8):709–733
|
–
|
|
15. Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic
purpura, and ADAMTS-13. Semin Thromb Hemost 2012;38(1):47–54
|
2014
|
|
16. Althaus K, Greinacher A. MYH9-related platelet disorders. Semin Thromb Hemost
2009;35(2):189–203
|
–
|
|
17. Bunimov N, Fuller N, Hayward CP. Genetic loci associated with platelet traits
and platelet disorders. Semin Thromb Hemost 2013;39(3):291–305
|
–
|
|
18. Kenet G, Aronis S, Berkun Y, et al. Impact of persistent antiphospholipid antibodies
on risk of incident symptomatic thromboembolism in children: a systematic review and
meta-analysis. Semin Thromb Hemost 2011;37(7):802–809
|
2014
|
|
19. Zolfaghari S, Harenberg J, Froelich L, Wehling M, Weiss C. Development of a tool
to identify patients' preference for vitamin K antagonist or direct oral anticoagulant
therapy. Semin Thromb Hemost 2014;40(1):121–128
|
–
|
|
20. Raskob GE, Angchaisuksiri P, Blanco AN, et al; ISTH Steering Committee for World
Thrombosis Day. Thrombosis: a major contributor to global disease burden. Semin Thromb
Hemost 2014;40(7):724–735
|
–
|
|
21. Demers M, Wagner DD. NETosis: a new factor in tumor progression and cancer-associated
thrombosis. Semin Thromb Hemost 2014;40(3):277–283
|
–
|
|
22. Wada H, Usui M, Sakuragawa N. Hemostatic abnormalities and liver diseases. Semin
Thromb Hemost 2008;34(8):772–778
|
–
|
|
23. Fareed J, Hoppensteadt DA, Fareed D, et al. Survival of heparins, oral anticoagulants,
and aspirin after the year 2010. Semin Thromb Hemost 2008;34(1):58–73
|
2010
|
|
24. Moore GW. Recent guidelines and recommendations for laboratory detection of lupus
anticoagulants. Semin Thromb Hemost 2014;40(2):163–171
|
–
|
|
25. Harenberg J, Kraemer S, Du S, et al. Determination of direct oral anticoagulants
from human serum samples. Semin Thromb Hemost 2014;40(1):129–134
|
–
|
General Category
-
Tapson VF. Thrombolytic therapy for acute pulmonary embolism. Semin Thromb Hemost
2013;39(4):452–458
-
George JN, Charania RS. Evaluation of patients with microangiopathic hemolytic anemia
and thrombocytopenia. Semin Thromb Hemost 2013;39(2):153–160
Open Access Category
-
Hylek EM. Anticoagulation therapy for atrial fibrillation. Semin Thromb Hemost 2013;39(2):147–152
-
Rojas-Hernandez CM, Garcia DA. The novel oral anticoagulants. Semin Thromb Hemost
2013;39(2):117–126
All the authors of these award winning articles were thrilled to hear that their articles
had won an Eberhard F. Mammen most popular award, and provided the following additional
responses:
From Dr. Victor Tapson ([Fig. 1]), Professor of Medicine at Cedars-Sinai Medical Center (Los Angeles, CA):
I was delighted to hear that my article ‘Thrombolytic therapy for acute pulmonary
embolism’ had won an Eberhard Mammen Seminars in Thrombosis & Hemostasis 2015 most popular article award. The issues surrounding thrombolytic therapy continue
to be vexing to clinicians. Even 40 years after publication of Urokinase/Streptokinase
Pulmonary Embolism (PE) Trials, the indications for systemic thrombolysis, particularly
in submassive PE, remain cloudy. Although the largest study to date has indicated
no clear mortality difference when thrombolytics are administered in submassive PE,
a large meta-analysis subsequently suggested improved mortality in this group. Clearly,
these patients still require careful analysis of their clinical data including assessment
for bleeding risk. Recently, catheter-based therapy (with or without thrombolysis)
has entered the clinical arena, offering more clinical options but requiring analysis
of resources, interpretation of the available clinical data, and assessment of the
individual patient. We do not yet have clear guidelines, but we are moving in a good
direction. We are embarking on new trials in this field. Because of the acute nature
of these patients, the dilemma of whether to proceed with thrombolysis remains of
tremendous interest to clinicians. Dr. Eberhard Mammen went to medical school in Germany,
intending to take over his father's family practice. Those of us in the field of venous
thromboembolism are very fortunate that he ultimately became involved in research,
in addition to medical education and clinical practice.
Fig. 1 Dr. Victor Tapson.
From Dr. James N. George ([Fig. 2]), George Lynn Cross Professor, Medicine University of Oklahoma Health Sciences Center
(Oklahoma City, OK):
This project was part of Dr. Roseleen Charania's [[Fig. 3]] Hematology-Oncology fellowship effort. We have had a lot of experience with patients
who were initially suspected to have thrombotic thrombocytopenic purpura (TTP) but
subsequently were discovered to have another etiology for the microangiopathic hemolytic
anemia and thrombocytopenia. There have been many different etiologies. Dr. Charania's
goal was to describe how we evaluate these patients. She did a superb job organizing
our experience and presenting the critical points for patient evaluations. This was
a great clinical project for her. She and I both learned a lot.
Fig. 2 Dr. James N. George.
Fig. 3 Dr. Roseleen Charania.
From Dr. Elaine M. Hylek ([Fig. 4]), Director Thrombosis Clinic and Anticoagulation Service at Boston University Medical
Center (Boston, MA):
When I learned that I had received this award, I could not believe it. It is a true
honor, especially coming from this community. The world of thrombosis has grown increasingly
complex from basic mechanisms and treatments to the varied clinical settings and high-risk
patients. Understanding the risks and benefits and helping our patients and colleagues
make the most informed decisions was the overarching aim of this article.
Fig. 4 Dr. Elaine M. Hylek.
Dr. David Garcia ([Fig. 5]), Professor of Medicine, University of Washington (Seattle, Washington), provided
the following commentary:
I am honored to receive one of the Eberhard Mammen Seminars in Thrombosis & Hemostasis 2015 Most Popular Article Awards. In my position, I am often asked to write review
papers and I do occasionally wonder how many people benefit from the effort it takes
to complete such a manuscript. In this case, I had the help of a superb colleague,
Dr. Cristhiam Rojas-Hernandez (now a member of the Section of Benign Hematology at
MD Anderson Cancer Center) [[Fig. 6]]. We were fortunate to be invited to write this paper at a moment when there was
a great deal of recently published, clinically actionable information available about
the direct oral anticoagulants (DOACs), and I am very pleased to know that many Seminars
readers found our synthesis of the evidence to be useful.
Fig. 5 Dr. David Garcia.
Fig. 6 Dr. Cristhiam Rojas-Hernandez.
It is also interesting (as always) to reflect on some of the other most popular articles
which relate to a variety of topics within the field of thrombosis and hemostasis.
Of some continued interest, and analogous to previous years, is that many articles
from previous most popular award listings appear yet again ([Table 2]), and this highlights their perpetuating interest to our readership.
I would like as always to thank not only all of the authors listed in [Tables 1] and [2] but also the contributing authors that did not manage to make these listings, as
well as all the guest editors of issues recently published in Seminars in Thrombosis & Hemostasis. I look forward to seeing future listings!
